TG Therapeutics, Inc.
TGTX
$29.45
$0.6752.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 16.79% | 11.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.79% | 11.71% | |||
| Cost of Revenue | 21.86% | 0.92% | |||
| Gross Profit | 16.04% | 13.50% | |||
| SG&A Expenses | 10.44% | 29.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.28% | 43.46% | |||
| Operating Income | 304.12% | -71.21% | |||
| Income Before Tax | 465.47% | -78.52% | |||
| Income Tax Expenses | 569.85% | -80.77% | |||
| Earnings from Continuing Operations | 457.06% | -78.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 457.06% | -78.31% | |||
| EBIT | 304.12% | -71.21% | |||
| EBITDA | 303.89% | -71.19% | |||
| EPS Basic | 456.81% | -78.52% | |||
| Normalized Basic EPS | 465.24% | -78.72% | |||
| EPS Diluted | 466.67% | -79.97% | |||
| Normalized Diluted EPS | 466.19% | -78.85% | |||
| Average Basic Shares Outstanding | 0.04% | 0.99% | |||
| Average Diluted Shares Outstanding | -0.13% | 1.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||